Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
06 3월 2024 - 3:30PM
Transgene to Present New Data on TG4050, an Individualized Cancer
Vaccine, at AACR 2024
Poster presentation of new data from
ongoing randomized Phase I trial targeting head and neck
cancers
Strasbourg, France, March 6, 2024,
7:30 a.m. CET – Transgene (Euronext Paris: TNG), a
biotech company that designs and develops virus-based
immunotherapies for the treatment of cancer, will present a poster
on updated data from the ongoing randomized Phase I trial of TG4050
at the American Association for Cancer Research Annual
Meeting (AACR). The AACR will take place in San Diego, California,
USA, from April 5 to 10, 2024.
Poster details
Title: Personalized vaccine
TG4050 induces polyepitopic immune responses against private
neoantigens in resected HPV negative head and neck cancers
- Session title: Late-Breaking Research: Clinical Research 3
- Poster and abstract number: LB401
- Date and Time: Wednesday April 10, 2024, 9:00 a.m. – 12:30 p.m.
PDT
- Location: Poster Section 52, Board number 2
- Authors : A. Lalanne, C. Jamet, JP Delord, C. Ottensmeier,
C. Le Tourneau, A. Tavernaro, G. Lacoste, B. Bastien, M.
Brandely, B. Grellier, E. Quemeneur, Y. Yamashita, O. Kousuke,
N. Yamagata, Y. Tanaka, K. Onoguchi, I. G. Pait, B. Malone,
O. Baker, P. Brattas, M. Gheorghe, R. Stratford, T. Clancy, K.
Bendjama, O. Lantz
The abstract will be available on the AACR
website April 5, 2024, at 3:00 p.m. ET / 9:00 p.m. CET.
TG4050 is an individualized immunotherapy being
developed for solid tumors that is based on Transgene’s myvac®
technology and powered by NEC’s longstanding artificial
intelligence (AI) and machine learning (ML) expertise. TG4050 is
being evaluated in a randomized multicenter Phase I clinical trial
as a single agent in the adjuvant treatment of HPV-negative head
and neck cancers (NCT04183166). Transgene and NEC plan to continue
the development of TG4050 in this indication with a Phase II
extension of the trial expected to start in 2024. TG4050 is being
jointly developed by Transgene and NEC.
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic
viruses based on the Invir.IO® viral backbone. With Transgene’s
myvac® platform, therapeutic vaccination enters the field of
precision medicine with a novel immunotherapy that is fully
tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.frFollow us on social
media: X (previously-Twitter): @TransgeneSA – LinkedIn:
@Transgene
Contacts
Transgene:Lucie LarguierVP,
Corporate Communications &
IR+33 (0)3 88 27 91 04investorrelations@transgene.fr |
Media: MEDiSTRAVA Frazer Hall
/Sylvie Berrebi+44
(0)203 928 6900transgene@medistrava.com |
Disclaimer
This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
- 20240306-Transgene_AACR_curtain_Raiser_TG4050_EN
Transgene (EU:TNG)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Transgene (EU:TNG)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024